Advertisement

Preventing Heart Failure by Treating Systolic Hypertension: What Does the SPRINT Add?

  • Bharathi UpadhyaEmail author
  • Richard B. Stacey
  • Dalane W. Kitzman
Hypertension and the Heart (Bharathi Upadhya, Section Editor)
  • 98 Downloads
Part of the following topical collections:
  1. Topical Collection on Hypertension and the Heart

Abstract

Purpose of Review

Previous trials definitively established that lowering systolic blood pressure (BP) to 140 mmHg prevented heart failure (HF) exacerbations, but the potential benefits and risks of further BP reduction remain unclear due to a paucity of trial-based data.

Recent Findings

A recent secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) found that in older, high-risk, non-diabetic participants with systolic hypertension, a BP treatment target < 120 mmHg resulted in a 36% lower rate of acute decompensated HF as compared with a BP target < 140 mmHg. Those participants with incident HF had a 26-fold increased risk of subsequent cardiovascular events and death. Based in part on the SPRINT results, the 2017 American Heart Association/American College of Cardiology/HF Society Guideline for the Management of HF acknowledged that targeting a significant reduction in BP in those at increased risk for cardiovascular disease is a novel risk-based strategy to prevent HF.

Summary

SPRINT redefines systolic BP target goals in older, high-risk patients and provides a key opportunity for preventing HF in this patient group.

Keywords

Heart failure Systolic hypertension Prevention Systolic blood pressure SPRINT 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Kitzman declares the following relationships: consultant for Abbvie, Bayer, Merck, Medtronic, GSK, Relypsa, Regeneron, Merck, Corvia Medical, DCRI, and Actavis, research grant funding from Novartis, St. Luke’s Medical Center, and stock ownership in Gilead Sciences. Dr. Upadhya has received research funding from Novartis and Corvia.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.CrossRefGoogle Scholar
  2. 2.
    Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628–37.CrossRefGoogle Scholar
  3. 3.
    Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–62.CrossRefGoogle Scholar
  4. 4.
    Johnson DB, Dell’Italia LJ. Cardiac hypertrophy and failure in hypertension. Curr Opin Nephrol Hypertens. 1996;5:186–91.CrossRefGoogle Scholar
  5. 5.
    Kizer JR, Arnett DK, Bella JN, Paranicas M, Rao DC, Province MA, et al. Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network Study. Hypertension. 2004;43:1182–8.CrossRefGoogle Scholar
  6. 6.
    Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension. 2005;46:124–9.CrossRefGoogle Scholar
  7. 7.
    Sharp A, Tapp R, Francis DP, McG Thom SA, Hughes AD, Stanton AV, et al. Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol. 2008;52:1015–21.CrossRefGoogle Scholar
  8. 8.
    Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550–8.CrossRefGoogle Scholar
  9. 9.
    Krumholz HM, Larson MG, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25:879–84.CrossRefGoogle Scholar
  10. 10.
    Cohen RA, Tong X. Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease. J Cardiovasc Pharmacol. 2010;55:308–16.CrossRefGoogle Scholar
  11. 11.
    de Simone G, Devereux RB, Izzo R, Girfoglio D, Lee ET, Howard BV, et al. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study. J Am Heart Assoc. 2013;2:e000144.CrossRefGoogle Scholar
  12. 12.
    Solomon S, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95.CrossRefGoogle Scholar
  13. 13.
    Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation. 2017;136:440–50.CrossRefGoogle Scholar
  14. 14.
    Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068–72.CrossRefGoogle Scholar
  15. 15.
    Beckett S, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.CrossRefGoogle Scholar
  16. 16.
    Kostis J, Davis BR, Cutler JA, Grimm RH Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212–6.CrossRefGoogle Scholar
  17. 17.
    Stassen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757–64.CrossRefGoogle Scholar
  18. 18.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.CrossRefGoogle Scholar
  19. 19.
    ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;363:1563–74.Google Scholar
  20. 20.
    Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525–33.CrossRefGoogle Scholar
  21. 21.
    • Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16 This multicenter randomized trial of intensive (target < 120/80 mmHg) compared to standard (target < 140/90 mmHg) hypertension treatment in high-risk, non-diabetic patients, showed significant reduction in the primary composite endpoint and in all-cause mortality with intensive treatment. CrossRefGoogle Scholar
  22. 22.
    • Upadhya B, Rocco M, Lewis CE, Oparil S, Lovato LC, Cushman WC, et al. Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial. Circ Heart Fail. 2017;10:e003613 A secondary analysis from SPRINT focused on incident heart failure in 6 pre-specified subgrops, and showed significant reduction in risk of incident heart failure with intensive treatment. CrossRefGoogle Scholar
  23. 23.
    • Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial. JAMA. 2016;315:2673–82 A secondary analysis from SPRINT, focusing in participants over 75 years of age at enrollment, showed consistent benefit of intensive treatment for the primary composite outcome and for indicent heart failure. In addition, exploratory analysis suggested that the benefit of intensive BP control was consistent among elderly persons (≥ 75 years) who were frail or had reduced gait speed.CrossRefGoogle Scholar
  24. 24.
    Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208–14.CrossRefGoogle Scholar
  25. 25.
    Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009–20.CrossRefGoogle Scholar
  26. 26.
    Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54:1827–34.CrossRefGoogle Scholar
  27. 27.
    McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol. 2016;68:1713–22.CrossRefGoogle Scholar
  28. 28.
    Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67.CrossRefGoogle Scholar
  29. 29.
    Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure - meta-analyses of randomized trials. J Hypertens. 2016;34:373–84.CrossRefGoogle Scholar
  30. 30.
    Rosamond WD, Chang PP, Baggett C, Johnson A, Bertoni AG, Shahar E, et al. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail. 2012;5:152–9.CrossRefGoogle Scholar
  31. 31.
    Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78.CrossRefGoogle Scholar
  32. 32.
    Margolis KL, Palermo L, Vittinghoff E, Evans GW, Atkinson HH, Hamilton BP, et al. Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med. 2014;29:1599–606.CrossRefGoogle Scholar
  33. 33.
    Gangavati A, Hajjar I, Quach L, Jones RN, Kiely DK, Gagnon P, et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc. 2011;59:383–9.CrossRefGoogle Scholar
  34. 34.
    Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;130:707–19.CrossRefGoogle Scholar
  35. 35.
    Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT results to the U.S. adult population. J Am Coll Cardiol. 2016;67:463–72.CrossRefGoogle Scholar
  36. 36.
    Bress AP, Kramer H, Khatib R, Beddhu S, Cheung AK, Hess R, et al. Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: projections from NHANES (National Health and Nutrition Examination Survey). Circulation. 2017;135:1617–28.CrossRefGoogle Scholar
  37. 37.
    Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142–61.CrossRefGoogle Scholar
  38. 38.
    • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–324 Guideline document from the American College of Cardiology and the American Heart Association with proposed diagnostic and therapeutic strategies for hypertension. CrossRefGoogle Scholar
  39. 39.
    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.CrossRefGoogle Scholar
  40. 40.
    Johnson KC, Whelton PK, Cushman WC, Cutler JA, Evans GW, Snyder JK, et al. Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2018;71:848–57.CrossRefGoogle Scholar
  41. 41.
    Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension. 2016;67:808–12.CrossRefGoogle Scholar
  42. 42.
    Drawz PE, Pajewski NM, Bates JT, Bello NA, Cushman WC, Dwyer JP, et al. Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure: results from the SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory blood pressure study. Hypertension. 2017;69:42–50.CrossRefGoogle Scholar
  43. 43.
    Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, et al. Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32:569–88.CrossRefGoogle Scholar
  44. 44.
    National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults - 2016. Melbourne: National Heart Foundation of Australia, 2016; 2016. Ref Type: GenericGoogle Scholar
  45. 45.
    • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Cardiol. 2017;70:776–803 Acknowledged that targeting a significant reduction in BP in those at increased risk for CVD is a novel risk-based strategy to prevent HF. The guideline states that in hypertensive patients at increased risk (stage A HF), optimal BP is < 130/80 mmHg. This recommendation reflects the assumption that BP measurements taken in the office setting are typically 5–10 mmHg higher than research-based measurements, as in SPRINT, so the < 130/80 mmHg goal is an approximation of the SPRINT intensive target BP adapted for conventional practice. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Bharathi Upadhya
    • 1
    Email author
  • Richard B. Stacey
    • 1
  • Dalane W. Kitzman
    • 1
  1. 1.Cardiovascular Medicine Section, Department of Internal MedicineWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations